Relationship between the site of esophageal carcinoma and survival of patients with locally advanced disease Authors: Andrea Masarykova, Ingrid Zavacka,

Slides:

Advertisements

Similar presentations

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.

Advertisements

Carcinoma of the Cardia: Is there progress in the management of non-Barrett’s cancer Spanish Association of Surgeons Madrid 11 November 2002 The University.

 DISCUSSION Number of resected lymph nodes in esophageal surgery has been previously discussed as for its probable impact on patients’ survival [4]. The.

CA Esophagus – Role of Chemoirradiation WH Chan Pamela Youde Nethersole Eastern Hospital.

Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.

Joint Hospital Surgical Grand Round KL FOK NDH/AHNH Department of Surgery.

ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.

62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.

Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.

Prostate Cancer Int. 洪毓謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:

A Propensity-matched Study of Lobectomy Versus Segmentectomy for Radiologically Pure Solid Small-sized Non-small Cell Lung Cancer Terumoto Koike 1, Seijiro.

Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.

INTRODUCTION  The majority of clinical trials addressing outcomes in limited- stage small cell lung cancer (LS-SCLC) following definitive chemoradiotherapy.

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.

Pneumonectomy for Locally Advanced Lung Cancer after Neoadjuvant Concurrent Chemo-radiation Therapy K. Okabe, H. Tao, T. Tanaka, T. Hayashi, K. Yoshiyama,

Clinical Outcomes and Patterns of Failure in Pineoblastoma: A 30-year Single Institution Experience Benjamin Farnia, B.A. ASTRO Poster Discussion September.

Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,

Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,

Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.

Phase Ⅱ Trial of Docetaxel and Cisplatin Neoadjuvant Chemotherapy Followed by Intensity-modulated Radiotherapy with Concurrent Cisplatin in Locally Advanced.

High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.

J. Lujan, G. Valero, Q. Hernandez, A. Sanchez, M.D. Frutos and P. Parrilla. British Journal of Surgery, September 2009.

What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Addition of Chemotherapy to Preoperative Radiotherapy Improves Outcomes in Rectal Cancer Slideset on: Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal.

Fig. 1: Regional abdominal lymph node dissection during 2-field LND. Fig. 2: full mobilisation of spleen and pancreatic tail to allow complete LND of.

Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,

DEPT OF RADIATION ONCOLOGY Prognostic Value of Post-Radiotherapy FDG PET in Head and Neck Cancer after Intensity Modulated Radiation Treatment Heming Lu.

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,

Perioperative Complications after Neoadjuvant Chemoradiation for Locally-Advanced Esophageal Cancer: A Comparison of Platinum/5-FU and Carboplatin/Paclitaxel.

Esophagectomy for cancer:

Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Results of Definitive Radiotherapy in Anal Canal Carcinoma

AUTHORS: DR VERNA VANDERPUYE,: DR JOEL YARNEY,: FRANCIS ASAMOAH:

Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.

Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.

A Hussain, S Qadri, Y Haqzad, M Chaudhry, A Cale, M Cowen, M Loubani.

Compassionate People World Class Care

Outcomes of patients in the North Trent region with advanced non-small-cell lung cancer treated with maintenance pemetrexed following induction with platinum.

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.

Prognosis of younger patients in non-small cell lung cancer

Department of Surgery, Taipei Veterans General Hospital Huang Kuo-Hung

Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.

What is the optimal pre-op therapy for esophagus and GE junction cancers?

Satya Shanbhag Waikato Cardiothoracic Unit

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Surgery vs. primary radiotherapy in early-stage oropharyngeal cancer

Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality.

Postoperative Adjuvant Therapy Improves Survival in Pathologic Nonresponders After Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma:

Clinical responses in patients.

ALLPPT.com _ Free PowerPoint Templates, Diagrams and Charts

Brendon M. Stiles, MD, Mohamed K. Kamel, MD, Sebron W

Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Liru He, MD, Pamela K. Allen, PhD, Adam.

Treated with Neoadjuvant Therapy

Role for XRT in treatment of early stage Follicular lymphoma?

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Carcinoma of the esophagus: Prognostic significance of histologic type

The Results of Radiotherapy in Childhood Neuroblastomas:

Prognosis of Patients With Pathologic T0 N+ Esophageal Squamous Cell Carcinoma After Chemoradiotherapy and Surgical Resection: Results From a Nationwide.

Primary Small Cell Carcinoma of the Esophagus

Table 1: According to IRS V staging p<0.001

Trends in survival from metastatic lung cancer in California,

Survival Benefits of Postoperative Chemoradiation for Lymph Node–Positive Esophageal Squamous Cell Carcinoma Po-Kuei Hsu, MD, Chien-Sheng Huang, MD,

Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Detailed Analysis of Prognostic Factors in Primary Esophageal Small Cell Carcinoma Wei-Wei Chen, MD, Feng Wang, MD, PhD, ShaoBin Chen, MD, Luhua Wang,

Presentation transcript:

Relationship between the site of esophageal carcinoma and survival of patients with locally advanced disease Authors: Andrea Masarykova, Ingrid Zavacka, Danijela Scepanovic, Marin Dzongov, Martina Pohrancova, Zuzana Dolinska, Margita Pobijakova Hospital: Department of Radiation Oncology, National Cancer Institute, Bratislava, Slovakia OBJECTIVES METHODS Background. – In the time of diagnosis esophageal carcinoma is still locally advanced disease for majority of patients. Different treatment modalities were tried, however, it is remained disease with poor prognosis and median survival less than 10 months. The adult human esophagus is an 18- to 25-cm long muscular tube that has cervical, thoracic, and abdominal parts. We analyzed relationship between the site of esophageal carcinoma and survival of our patients with locally advanced disease. A total of 70 patients with locally advanced esophageal carcinoma (66 male and 4 female) underwent an radiotherapy (RT) with/without chemotherapy (ChT) or surgery. There were 4 patients who performed only RT, 27 patients concomitant ChT/RT, 19 patients concomitant ChT/RT followed by surgery and 20 patients with concomitant ChT/RT followed by intraluminal brachytherapy (ILBT) during the period from 2008 to 2015. Median age was 64 (range, 47-84). Squamous cell esophageal cancer has been represented in 77% patients and a remnant were adenocarcinomas. Eleven patients had carcinoma located in the cervical esophagus, 37 in thoracic and 22 patients in abdominal site of the esophagus. Graphs and tables RESULTS The median follow up for all patients was 16 months (range, 4-108). Locoregional recurrence rate was 6% for patients in the cervical, 9% in thoracic and 6% in abdominal site of disease (p=0.38731072). Distant recurrence rate was 6%, 13% and 13% for cervical, thoracic and abdominal site, respectively (p=0.35749874). In the group of patients with cervical site of disease only one patient was alive, 5 patients with thoracic site and 5 patients with abdominal site of disease (p=0.60045413). The 2- and 3-year overall survival rate for cervical, thoracic and abdominal site was 36% and 9%; 35% and 30%; 36 and 27%, respectively. Only seven of 70 patients showed a long-term survival of longer than 3 years. CONCLUSIONS References Deng HY, Wang WP, Wang YC, et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer. European Journal of Cardio-Thoracic Surgery 0 (2016) 1–11 doi:10.1093/ejcts/ezw315 Markar SR, Noordman BJ, Mackenzie H, et al. Multimodality treatment for esophageal adenocaricnoma: multi-center propensity-score matched study. Annals of Oncology 0: 1–8, 2016 doi:10.1093/annonc/mdw560 In conclusion, our study suggests that anatomical site of disease is not significant prognostic factor for survival of the patients with locally advanced esophageal cancer.